MétaCan
Menu
Back to cohort
Record W2012297324 · doi:10.1111/joim.12065

Endocrine therapy: is the first generation of targeted drugs the last?

2013· review· en· W2012297324 on OpenAlexaff
Kathleen I. Pritchard

Bibliographic record

VenueJournal of Internal Medicine · 2013
Typereview
Languageen
FieldMedicine
TopicAdvanced Breast Cancer Therapies
Canadian institutionsUniversity of Toronto
Fundersnot available
KeywordsLapatinibMedicineEverolimusTrastuzumabTamoxifenTargeted therapyBreast cancerOncologyHormonal therapyInternal medicineEndocrine systemAromatase inhibitorCancerCancer researchPI3K/AKT/mTOR pathwayEstrogen receptorHormoneSignal transductionBiology

Abstract

fetched live from OpenAlex

Hormonal therapy for breast cancer is the first targeted therapy used in any type of cancer. It was used successfully without a known target for more than 50 years before Jensen described the oestrogen receptor (ER) in the 1960s. Subsequently, it was found that endocrine therapy was effective only in those patients whose tumours expressed the ER; more recently, it has been recognized that this therapy can also be effective in some patients whose tumours are ERα-negative but ERβ-positive. However, in spite of the ER being present, many tumours develop either primary or secondary resistance to various endocrine approaches. ER-containing tumours may also be classified by molecular markers as luminal A (highly hormone responsive) or luminal B (high degree of proliferation and less hormone responsiveness). Furthermore, the expression of ER, progesterone receptor and human epidermal growth factor receptor 2 (HER2) may change over time as tumours metastasize and progress. The addition of anti-HER2 agents such as trastuzumab and lapatinib to hormonal therapies has improved outcomes but it is unclear whether these approaches are additive or synergistic. Now, mammalian target of rapamycin (mTOR) inhibitors are being successfully used in similar scenarios but once again it is unclear whether the effect of this combination therapy is synergistic; however, mTOR inhibitors produce little response as single agents. In particular, the addition of the mTOR inhibitor everolimus has improved disease-free and overall survival in randomized studies in metastatic disease when added either to an aromatase inhibitor or to tamoxifen. To date, however, no specific biomarkers for the use of everolimus have been reported. Further studies are needed to identify and validate targets of therapy in endocrine-responsive breast cancer.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.973
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.058
GPT teacher head0.359
Teacher spread0.301 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations45
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Internal MedicineSame topicAdvanced Breast Cancer TherapiesFrench-language works237,207